Kuhnil & Daiichi Sankyo’s joint sales of dyslipidemia treatment ‘Mevalotin’

Published: 2017-03-29 14:48:25

Updated: 2017-03-29 14:48:25

For ‘Mevalotin(generic name: pravastatin),’ the dyslipidemia treatment, Kuhnil Pharm(CEO Young-Joong Kim) and Daiichi Sankyo Korea(CEO Dae-Joong Kim) will started the joint sales from the 1^st of April.

Daiichi Sankyo Korea will end the joint marketing with LG Chem on the 31^st of March and chose Kuhnil Pharm as a new partner. Daiichi Sankyo Korea and Kuhnil Pharm are planning to take charge in ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.